{"id":"W4402560121","doi":"10.1016/j.annonc.2024.08.685","title":"618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006004468,0.0003818912,0.001117927,0.0006860185,0.0001097327,0.00003363333,0.00007916438,0.0002249774,0.00003639981],"category_scores_gemma":[0.0002162718,0.0003735927,0.0001031158,0.0008475415,0.0003241145,0.001011803,0.0000655746,0.0004248228,0.000001347213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005519239,"about_ca_system_score_gemma":0.0007983365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000612414,"about_ca_topic_score_gemma":0.002851241,"domain_scores_codex":[0.9972085,0.0001945697,0.001064637,0.0007133288,0.0003618257,0.0004571008],"domain_scores_gemma":[0.9982709,0.0002919096,0.0004778974,0.0001970874,0.0006209196,0.0001413126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02716007,0.00334779,0.0003380307,0.0004555385,0.0003838979,0.00006280436,0.006150781,0.00141092,0.6196131,0.0008009996,0.0004170345,0.339859],"study_design_scores_gemma":[0.2280119,0.03895416,0.009412819,0.002275773,0.0006419981,0.000643459,0.002549282,0.1025397,0.6038931,0.002260868,0.007417349,0.001399591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853114,0.00425516,0.0006065369,0.00696268,0.000706103,0.001855572,0.000165152,0.00003879381,0.00009858738],"genre_scores_gemma":[0.9958478,0.00125346,0.0009618109,0.0004653308,0.00073547,0.0004778928,0.0001118023,0.00005992764,0.00008649903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3384594,"threshold_uncertainty_score":0.9998716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08902763781321484,"score_gpt":0.3976565212249891,"score_spread":0.3086288834117742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}